Urology Times wants your stories.
If your practice was recently bought or sold, we want to hear from you. What did you learn? What would you do differently if you could do it over?
To contribute your own experience, simply fill out the comment box on this page.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.